Biotinylated PD-1/PDCD1, Human Recombinant
PDCD1, PD1, CD279, SLEB2, hPD-1, hPD-l
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q15116 |
---|---|
Calculated MW | 19.7 kDa |
Gene ID | 5133 |
---|---|
Other Names | PDCD1, PD1, CD279, SLEB2, hPD-1, hPD-l |
Gene Source | Human |
Source | E. coli |
Assay&Purity | SDS-PAGE;> 90% |
Assay2&Purity2 | SEC;> 90% |
Recombinant | Yes |
Target/Specificity | PD1 |
Format | Liquid |
Storage | -20°C;0.5 mg/ml solution in in PBS containing 20% glycerol |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Programmed death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer. This protein is suitable for use in protein studies such as protein structure analysis and protein-protein interactions. It can also be used as an immunogen, as a protein standard, or in cell biology research applications.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.